Having previously shown that the combination of HSV oncolytic virotherapy and BRAFi is effective in BRAF mutant thyroid cancer,8 we wished to test this approach in the clinically more common setting for use of these drugs, namely melanoma. The gene discussed is BRAF; the disease is thyroid gland carcinoma.